This page contains a Flash digital edition of a book.
Non-motor Symptoms in Parkinson’s Disease


78. Krogh K, Ostergaard K, Sabroe S, et al., Clinical aspects of bowel symptoms in Parkinson's disease, Acta Neurol Scand, 2008;117:60–4.


79. Wang G, Wan Y, Cheng Q, et al., Malnutrition and associated factors in Chinese patients with Parkinson's disease: Results from a pilot investigation, Parkinsonism Relat Disord, 2010;16:119–23.


80. Goetze O, Nikodem AB, Wiezcorek J, et al., Predictors of gastric emptying in Parkinson's disease, Neurogastroenterol Motil, 2006;18:369–75.


81. Goetze O, Wieczorek J, Mueller T, et al., Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test, Neurosci Lett, 2005;375:170–3.


82. Krygowska-Wajs A, Cheshire WP, Jr, Wszolek ZK, et al., Evaluation of gastric emptying in familial and sporadic Parkinson disease, Parkinsonism Relat Disord, 2009;15:692–6.


83. Jost WH, Gastrointestinal dysfunction in Parkinson's disease, J Neurol Sci, 2010;289:69–73.


84. Lebouvier T, Chaumette T, Damier P, et al., Pathological lesions in colonic biopsies during Parkinson's disease, Gut, 2008;57:1741–3.


85. Petrovitch H, Abbott RD, Ross GW, et al., Bowel movement frequency in late-life and substantia nigra neuron density at death, Mov Disord, 2008;24:371–6.


86. Taylor TN, Caudle WM, Shepherd KR, et al., Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity, J Neurosci, 2009;29:8103–13.


87. Kuo YM, Li, Z, Jiao Y, et al., Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes, Hum Mol Genet, 2010;19:1633–50.


88. Chaumette T, Lebouvier T, Aubert P, et al., Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism, Neurogastroenterol Motil, 2009;21:215–22.


89. Blandini F, Balestra B, Levandis G, et al., Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease, Neurosci Lett, 2009;467:203–7.


90. Greene JG, Noorian AR, Srinivasan S, Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease, Exp Neurol, 2009;218:154–61.


91. Drolet RE, Cannon JR, Montero L, et al., Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology, Neurobiol Dis, 2009;36:96–102.


92. Morgan JC, Sethi KD, Tegaserod in constipation associated with Parkinson disease, Clin Neuropharmacol, 2007;30:52–4.


93. Sullivan KL, Staffetti JF, Hauser RA, et al., Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease, Mov Disord, 2006;21:115–6.


94. Zangaglia R, Martignoni E, Glorioso M, et al., Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study, Mov Disord, 2007;22:1239–44.


95. Zibetti M, Torre E, Cinquepalmi A, et al., Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus, Eur Neurol, 2007;58:218–23.


96. Asai H, Udaka F, Hirano M, et al., Increased gastric motility during 5-HT(4) agonist therapy reduces response fluctuations in Parkinson's disease, Parkinsonism Relat Disord, 2005;11:499–502.


97. Adhiyaman V, Hobson P, Meara RJ, Central and peripheral autonomic integrity in Parkinson's disease, Age Ageing, 2008;37:578–81.


98. Pandya M, Kubu CS, Giroux ML, Parkinson disease: not just a movement disorder, Cleve Clin J Med, 2008;75:856–64.


99. Goldstein DS, Holmes CS, Dendi R, et al., Orthostatic hypotension from sympathetic denervation in Parkinson's disease, Neurology, 2002;58:1247–55.


100. Senard JM, Chamontin B, Rascol A, et al., Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension, Clin Auton Res, 1992;2:99–104.


101. Araki I, Kuno S, Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score, J Neurol Neurosurg Psychiatry, 2000;68:429–33.


102. Winge K, Skau AM, Stimpel H, et al., Prevalence of bladder dysfunction in Parkinsons disease, Neurourol Urodyn, 2006;25:116–22.


103. Winge K, Nielsen KK, Stimpel H, et al., Lower urinary tract symptoms and bladder control in advanced Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus, Mov Disord, 2007;22:220–5.


104. Sakakibara R, Uchiyama T, Yamanishi T, et al., Genitourinary dysfunction in Parkinson's disease, Mov Disord, 2010;25:2–12.


105. Blackett H, Walker R, Wood B, Urinary dysfunction in Parkinson's disease: a review, Parkinsonism Relat Disord, 2009;15:81–7.


106. Seif C, Herzog J, van der HC, et al., Effect of subthalamic deep brain stimulation on the function of the urinary bladder, Ann Neurol, 2004;55:118–20.


107. Winge K, Friberg L, Werdelin L, et al., Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease, Eur J Neurol, 2005;12:842–50.


108. Hineno T, Mizobuchi M, Hiratani K, et al., Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs, Brain Res, 1992;580:92–9.


109. Menza M, Dobkin RD, Marin H, et al., Sleep disturbances in Parkinson's disease, Mov Disord, 2010;25(Suppl. 1):S117–S22.


110. Sakakibara R, Hattori T, Uchiyama T, et al., Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy, J Neurol Neurosurg Psychiatry, 2001;71:600–6.


111. Bennett N, O'Leary M, Patel AS, et al., Can higher doses of oxybutynin improve efficacy in neurogenic bladder?, J Urol, 2004;171:749–51.


112. Ehrt U, Broich K, Larsen JP, et al., Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study, J Neurol Neurosurg Psychiatry, 2010;81:160–5.


113. Cooper JA, Sagar HJ, Doherty SM, et al., Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients, Brain, 1992;115(Pt 6):1701–25.


114. Andersson KE, Treatment of overactive bladder: other drug mechanisms, Urology, 2000;55:51–7.


115. Giannantoni A, Rossi A, Mearini E, et al., Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy, J Urol, 2009;182:1453–7.


116. Neu HC, Connolly JJ Jr, Schwertley FW, et al., Obstructive respiratory dysfunction in parkinsonian patients, Am Rev Respir Dis, 1967;95:33–47.


117. Estenne M, Hubert M, De Troyer A, Respiratory-muscle involvement in Parkinson's disease, N Engl J Med, 1984;311:1516–7.


118. Canning CG, Alison JA, Allen NE, et al., Parkinson's disease: an investigation of exercise capacity, respiratory function, and gait, Arch Phys Med Rehabil, 1997;78:199–207.


119. Pitts T, Bolser D, Rosenbek J, et al., Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease, Chest, 2009;135:1301–8.


120. Troche MS, Okun MS, Rosenbek JC, et al., Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial, Neurology, 2010;75:1912–9.


121. Schiermeier S, Schafer D, Schafer T, et al., Breathing and locomotion in patients with Parkinson's disease, Pflugers Arch, 2001;443:67–71.


122. Reuter I, Engelhardt M, Freiwaldt J, et al., Exercise test in Parkinson's disease, Clin Auton Res, 1999;9:129–34.


123. Tandberg E, Larsen JP, Karlsen K, A community-based study of sleep disorders in patients with Parkinson's disease, Mov Disord, 1998;13:895–9.


124. Porter B, Macfarlane R, Walker R, The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease, Eur J Neurol, 2008;15:50–4.


125. Comella CL, Sleep disturbances in Parkinson's disease, Curr Neurol Neurosci Rep, 2003;3:173–80.


126. Askenasy JJ, Yahr MD, Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study, Neurology, 1985;35:527–32.


127. Cicolin A, Lopiano L, Zibetti M, et al., Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients, Sleep Med, 2004;5:207–10.


128. Comella CL, Morrissey M, Janko K, Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy, Neurology, 2005;64:1450–1.


129. Suzuki K, Okuma Y, Hattori N, et al., Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale, Mov Disord, 2007;22:1245–51.


130. Garcia-Borreguero D, Odin P, Serrano C, Restless legs syndrome and PD: a review of the evidence for a possible association, Neurology, 2003;61:S49–S55.


131. Happe S, Trenkwalder C, Movement disorders in sleep: Parkinson's disease and restless legs syndrome,


Biomed Tech (Berl), 2003;48:62–7.


132. Pittock SJ, Joyce C, O'Keane V, et al., Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred, Neurology, 2000;55:991–5.


133. Maria B, Sophia S, Michalis M, et al., Sleep breathing disorders in patients with idiopathic Parkinson's disease, Respir Med, 2003;97:1151–7.


134. Trotti LM, Bliwise DL, No increased risk of obstructive sleep apnea in Parkinson's disease, Mov Disord, 2010;25:2246–9.


135. Punjabi NM, The epidemiology of adult obstructive sleep apnea, Proc Am Thorac Soc, 2008;5:136–43.


136. Arnulf I, Leu-Semenescu S, Sleepiness in Parkinson's disease, Parkinsonism Relat Disord, 2009;15(Suppl. 3):S101–S4.


137. Gjerstad MD, Aarsland D, Larsen JP, Development of daytime somnolence over time in Parkinson's disease, Neurology, 2002;58:1544–6.


138. Suzuki K, Miyamoto T, Miyamoto M, et al., Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease, J Neurol Sci, 2008;271:47–52.


139. Kaynak D, Kiziltan G, Kaynak H, et al., Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment, Eur J Neurol, 2005;12:199–207.


140. Stevens S, Cormella CL, Stepanski EJ, Daytime sleepiness and alertness in patients with Parkinson disease, Sleep, 2004;27:967–72.


141. Arnulf I, Leu S, Oudiette D, Abnormal sleep and sleepiness in Parkinson's disease, Curr Opin Neurol, 2008;21:472–7.


142. Ondo WG, Fayle R, Atassi F, et al., Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial, J Neurol Neurosurg Psychiatry, 2005;76:1636–9.


143. Meindorfner C, Korner Y, Moller JC, et al., Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel, Mov Disord, 2005;20:832–42.


144. Gagnon JF, Bedard MA, Fantini ML, et al., REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease, Neurology, 2002;59:585–9.


145. Claassen DO, Josephs KA, Ahlskog JE, et al., REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century, Neurology, 2010;75:494–9.


146. Boeve BF, Silber MH, Ferman TJ, Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients, Sleep Med, 2003;4:281–4.


147. Ringman JM, Simmons JH, Treatment of REM sleep behavior disorder with donepezil: a report of three cases, Neurology, 2000;55:870–1.


148. Schmidt MH, Koshal VB, Schmidt HS, Use of pramipexole in REM sleep behavior disorder: results from a case series, Sleep Med, 2006;7:418–23.


149. Schenck CH, Mahowald MW, Kim SW, et al., Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder, Sleep, 1992;15:226–35.


150. Fiszer U, Michalowska M, Baranowska B, et al., Leptin and ghrelin concentrations and weight loss in Parkinson's disease, Acta Neurol Scand, 2010;121:230–6.


151. Delikanaki-Skaribas E, Trail M, Wong WW, et al., Daily energy expenditure, physical activity, and weight loss in Parkinson's disease patients, Mov Disord, 2009;24:667–71.


152. Aziz NA, van der Marck MA, Pijl H, et al., Weight loss in neurodegenerative disorders, J Neurol, 2008;255:1872–80.


153. Uc EY, Struck LK, Rodnitzky RL, et al., Predictors of weight loss in Parkinson's disease, Mov Disord, 2006;21:930–6.


154. Chen H, Zhang SM, Hernan MA, et al., Weight loss in Parkinson's disease, Ann Neurol, 2003;53:676–9.


155. Lorefalt B, Ganowiak W, Palhagen S, et al., Factors of importance for weight loss in elderly patients with Parkinson's disease, Acta Neurol Scand, 2004;110:180–7.


156. Strowd RE, Cartwright MS, Passmore LV, et al., Weight change following deep brain stimulation for movement disorders, J Neurol, 2010;257:1293–7.


157. Walker HC, Lyerly M, Cutter G, et al., Weight changes associated with unilateral STN DBS and advanced PD, Parkinsonism Relat Disord, 2009;15:709–11.


158. Wszolek ZK, Markopoulou K, Olfactory dysfunction in Parkinson's disease, Clin Neurosci, 1998;5:94–101.


159. Bohnen NI, Muller ML, Kotagal V, et al., Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease, Brain, 2010;133:1747–54.


160. Chaudhuri KR, Odin P, Antonini A, et al., Parkinson's disease: The non-motor issues, Parkinsonism Relat Disord, 2011;17:717–23.


US NEUROLOGY


119


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108